Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.35 |
| ▸ | IDO1 | P14902 | 6/20 | 0.35 |
| ▸ | TDO2 | P48775 | 5/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | PTGIS | Q16647 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20002512 | 0.82 | IDO1 (0.50) | CYP11B2TBXAS1IDO1TDO2PTGS1 | |
| SCHEMBL20001790 | 0.80 | IDO1 (0.50) | CYP11B2TBXAS1IDO1TDO2PTGS1 | |
| SCHEMBL18137634 | 0.77 | IDO1 (0.48) | CYP11B2TBXAS1IDO1TDO2PTGS1 | |
| SCHEMBL8745905 | 0.77 | RBP4 (0.40) | ACP3IDO1CNR2OPRM1OPRD1 | |
| SCHEMBL20001809 | 0.75 | IDO1 (0.55) | ACP3IDO1TDO2OPRM1OPRD1 | |
| SCHEMBL20001933 | 0.72 | TOP2A (0.37) | TBXAS1IDO1TDO2 | |
| SCHEMBL9776265 | 0.71 | ACP3 (0.50) | ACP3IDO1TDO2CNR2OPRM1 | |
| SCHEMBL30903830 | 0.71 | ACP3 (0.50) | ACP3IDO1TDO2CNR2OPRM1 | |
| SCHEMBL14904829 | 0.70 | TBXAS1 (0.47) | CYP11B2TBXAS1IDO1TDO2PTGS1 | |
| SCHEMBL18137404 | 0.70 | TBXAS1 (0.47) | CYP11B2TBXAS1IDO1TDO2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | ACP3 3833/4885CYP11B2 41/4885TBXAS1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.